Lynch Syndrome - Cancer Pathways, Heterogeneity and Immune Escape

Sidhant Seth, Ann Ager, Mark Arends, Ian M Frayling

Research output: Contribution to journalReview articlepeer-review


Recent work has provided evidence for genetic and molecular heterogeneity in colorectal cancers (CRCs) arising in patients with Lynch syndrome (LS), dividing these into two groups: G1 and G2. In terms of mutation and gene expression profile, G1 CRCs bear resemblance to sporadic CRCs with microsatellite instability (MSI), whereas G2 CRCs are more similar to microsatellite stable CRCs. Here we review the current state of knowledge on pathways of precursor progression to CRC in LS and how these might tie in with the new findings. Immunotherapies are an active field of research for MSI cancers and their potential use for cancer therapy for both sporadic and LS MSI cancers is discussed. This article is protected by copyright. All rights reserved.

Original languageEnglish
Pages (from-to)129-133
JournalThe Journal of Pathology
Issue number2
Early online date20 Jul 2018
Publication statusE-pub ahead of print - 20 Jul 2018


Dive into the research topics of 'Lynch Syndrome - Cancer Pathways, Heterogeneity and Immune Escape'. Together they form a unique fingerprint.

Cite this